Carmell Corp Ordinary Shares - Class A CTCX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CTCX is a good fit for your portfolio.
News
-
Carmell Announces Successful Closing of $3.0 Million Private Placement
-
Carmell Announces $3.0 Million Private Placement
-
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
-
Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary
-
Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field
-
Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024
Trading Information
- Previous Close Price
- $2.28
- Day Range
- $2.05–2.34
- 52-Week Range
- $1.70–13.31
- Bid/Ask
- $2.06 / $2.68
- Market Cap
- $42.50 Mil
- Volume/Avg
- 28,007 / 7,691
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Carmell Corp is a bio-aesthetics company that utilizes the Carmell Secretome to support skin and hair health. Its cosmetic skincare product portfolio includes Carmell G.L.E.E and various others in pipeline such as Youth restoring formula, Ultra-brightening formula, Ultra-hydrating formula, and Rapid Recovery formula among others. The company has one operating segment, principally the business of developing and commercializing bio-aesthetics and its bone and tissue healing products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 10
- Website
- https://www.carmellcorp.com
Valuation
|
Metric
|
CTCX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.13 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CTCX
|
|---|---|
Quick Ratio | 0.16 |
Current Ratio | 0.75 |
Interest Coverage | — |
Quick Ratio
CTCX
Profitability
|
Metric
|
CTCX
|
|---|---|
Return on Assets (Normalized) | −14.97% |
Return on Equity (Normalized) | −23.34% |
Return on Invested Capital (Normalized) | −21.88% |
Return on Assets
CTCX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pynkrxqn | Gtrd | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ytphjjcz | Zwhybq | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tvykhtgw | Jnqncv | $108.2 Bil | |
MRNA
| Moderna Inc | Qpswbyhn | Bwl | $50.9 Bil | |
ARGX
| argenx SE ADR | Qtvznct | Ffcj | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Spgqtgzby | Ptg | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Znlgsrj | Ftwtv | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mjgczfpf | Rlxzvv | $14.6 Bil | |
INCY
| Incyte Corp | Hxjbxcr | Hbnsg | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mdtnydvzk | Gkdmpf | $12.3 Bil |